158 related articles for article (PubMed ID: 19048780)
1. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
2. Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Lab Anim; 2009 Jul; 43(3):284-90. PubMed ID: 19237454
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Li WL; Xin HW; Su MW
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
[TBL] [Abstract][Full Text] [Related]
4. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.
Kim JS; Nafziger AN; Tsunoda SM; Choo EE; Streetman DS; Kashuba AD; Kulawy RW; Beck DJ; Rocci ML; Wilkinson GR; Greenblatt DJ; Bertino JS
J Clin Pharmacol; 2002 Apr; 42(4):376-82. PubMed ID: 11936561
[TBL] [Abstract][Full Text] [Related]
6. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
7. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.
Masters JC; Harano DM; Greenberg HE; Tsunoda SM; Jang IJ; Ma JD
Ther Drug Monit; 2015 Feb; 37(1):84-9. PubMed ID: 25004135
[TBL] [Abstract][Full Text] [Related]
8. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
[TBL] [Abstract][Full Text] [Related]
9. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
10. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
11. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
[TBL] [Abstract][Full Text] [Related]
13. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
14. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
[TBL] [Abstract][Full Text] [Related]
15. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
Fukuno S; Nagai K; Fujiike M; Sasaki Y; Konishi H
Xenobiotica; 2019 Dec; 49(12):1470-1477. PubMed ID: 30714842
[TBL] [Abstract][Full Text] [Related]
16. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
17. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
[TBL] [Abstract][Full Text] [Related]
18. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
19. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
[TBL] [Abstract][Full Text] [Related]
20. Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats.
Nagai K; Yoshida N; Kiyama M; Kasahara K; Yamamura A; Konishi H
Xenobiotica; 2015; 45(10):874-80. PubMed ID: 26053556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
